Cannabis Science Presents at World AIDS Institute Treatment Horizons Satellite Symposium during AIDS 2012 in Washington DC

Cannabis Science Presents at World AIDS Institute Treatment Horizons Satellite Symposium during AIDS 2012 in Washington DC

Dr. Robert J. Melamede, 1-888-889-0888President & CEOorRobert Kane, 1-561-234-6929VP Investor Relations

Cannabis Science Inc. (OTCBB:CBIS) announced today the presentation on the effects of phytocannabinoid inhibition on HIV TAT at the World AIDS Institute Treatment Horizons Satellite Symposium during AIDS 2012 in Washington DC on July 24. Dr. Robert Melamede presented to an audience of researchers, physicians, HIV patients and activists during the biennial conference sponsored by the International AIDS Society.

The 19 International AIDS Conference (AIDS 2012) took place in Washington DC on July 22-27 with over 24,000 delegates from across the globe in attendance. Leaders from the worlds of science, diplomacy, politics, philanthropy and entertainment addressed conference delegates from more than 183 countries. Speakers included President Bill Clinton, U.S. Secretary of State Hillary Rodham Clinton, Former U.S. First Lady Laura Bush, World Bank President Jim Yong Kim, Nobel Laureate Françoise Barré-Sinoussi, Rep. Barbra Lee (D.CA) and philanthropist Bill Gates.

“We are very happy for the opportunity to have discussed the use of phytocannabinoids as a therapeutic for HIV at AIDS 2012. This novel approach to attacking HIV could provide an alternative to those with few therapeutic options left due to severe side effects and HIV strains resistant to currently approved ARV’s,” stated Dr. Melamede.

Recent research at the Mt. Sinai School of Medicine collaborates earlier research that phytocannabinoids may inhibit HIV TAT’s mitigation. TAT (Trans-Activator of Transcription) is an HIV gene vital to HIV replication. Cannabis Science is initiating an HIV TAT Anti-Viral Drug Development Program to develop phytocannabinoid-based therapeutics to inhibit the gene. Cannabis Science’s research of CS-TATI-1 will be targeted to newly diagnosed patients infected with drug resistant virus, treatment experienced patients with drug-resistant HIV.

The Treatment Horizons Satellite Symposium sponsored by The World AIDS Institute, hosted a wide range of events during the weeks prior to and during AIDS 2012. Attendees at the symposium included scientists, doctors, clinicians, policy makers and leading AIDS treatment activists from around the world. Other presentations at the AIDS 2012 Treatment Horizons Satellite Symposium included maturing therapeutic options such as monoclonal antibodies, therapeutic vaccines and emerging antivirals sponsored by early stage biotech companies receiving federal support for continued research.

“We were delighted to have Dr. Melamede present at The Treatment Horizons Satellite Symposium on behalf of Cannabis Science. With the high cost of continual antiretroviral therapies and the side effects people living with HIV must endure, new therapies such as TAT Inhibitors are desperately needed,” stated Dave Purdy Executive Director of The World AIDS Institute.

The World AIDS Institute is led by Co-Executive Directors Dave Purdy and Chad Johnson launched the Timothy Ray Brown Foundation during AIDS 2012. The mission of the Washington DC based foundation is to support HIV cure research and initiatives. WAI also works to document and preserve the global history of AIDS, to inspire action today to improve the lives of people living with HIV and AIDS (and their family, friends, and communities), and to strengthen the spectrum of innovative initiatives to find a cure.

Cannabis Science, Inc. is conducting cannabinoid research and development for unmet medical needs. The Company works with leading experts in HIV drug development, medicinal characterization, and clinical research to develop, produce, and commercialize Phytocannabinoid-based pharmaceutical products.

Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas.

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Suggested Articles

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Vertex is keeping mum on exact details but, as with the rest of its biopharma peers, is seeing trial disruption due to the COVID-19 pandemic.

Companies including Novartis and Pfizer are contributing to the joint response through actions including the sharing of proprietary compounds